Answers are grounded in this paper and cite their sources.
The observed reduction in TNFR1, IL-6, MMP7 and FN1 suggests that canagliflozin contributes to reversing molecular processes related to inflammation, extracellular matrix turnover and fibrosis. Trial registration ClinicalTrials.gov NCT00968812.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: